| Released | Contributor | Author | Title | Pages | Price |
| 29-Nov-2009 | PriceTarget Research, Inc. |
N/A
| Allergan has a current Overall Rating of B (Positive). | 7 |
$25 |
| 27-Nov-2009 | Stock Traders Daily | Thomas H. Kee Jr. | Trading Report for (AGN). A detailed Technical Analysis + Trading Plans for Day Trading, Swing Trading, and Long Term proactive investments in (AGN). | 5 |
$18 |
| 27-Nov-2009 | Validea |
N/A
| Validea Guru Analysis Report for AGN. Analysis using Validea's interpretation of the published quantitative strategies of well-known Wall Street experts including Peter Lynch, Warren Buffett, Ben Graham and Ken Fisher, among others. | 0 |
$18 |
| 26-Nov-2009 | ValuEngine, Inc. |
N/A
| ValuEngine Industry Report for MEDICAL SUPPLIES | 18 |
$49 |
| 26-Nov-2009 | New Constructs, LLC |
N/A
| AGN: Updated Risk/Reward Rating: Full Report: Cash Truth Behind the Reported Earnings | 19 |
$10 |
| 26-Nov-2009 | Pechala's Reports | Lubomir Pechala | ALLERGAN INC (AGN=US) - REPORT FOR ACTIVE TRADERS | 4 |
$25 |
| 24-Nov-2009 | Jefferson Research |
N/A
| Jefferson Research Financial Sonar Report. A detailed analysis of the current fundamental performance of ALLERGAN INC including Earnings Quality, Cash Flow Quality, Operating Efficiency, Balance Sheet Quality and Valuation. | 3 |
$20 |
| 23-Nov-2009 | Reuters Investment Profile |
N/A
| Allergan Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis. | 12 |
$20 |
| 23-Nov-2009 | Plunkett Research, Ltd. | Jack W. Plunkett | Engineering & Research Industry Trends, Statistics & Analysis 2009 (Summary) | 70 |
$199 |
| 23-Nov-2009 | Plunkett Research, Ltd. | Jack W. Plunkett | Biotech & Genetics Industry Trends, Statistics & Analysis 2010 (Summary) | 71 |
$199 |
1.48% Nasdaq 
Research Reports
